These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37274183)

  • 1. Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine.
    Shrestha NK; Burke PC; Nowacki AS; Simon JF; Hagen A; Gordon SM
    Open Forum Infect Dis; 2023 Jun; 10(6):ofad209. PubMed ID: 37274183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the 2023-2024 Formulation of the COVID-19 Messenger RNA Vaccine.
    Shrestha NK; Burke PC; Nowacki AS; Gordon SM
    Clin Infect Dis; 2024 Aug; 79(2):405-411. PubMed ID: 38465901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Coronavirus Disease 2019 (COVID-19) among those up-to-date and not up-to-date on COVID-19 vaccination by US CDC criteria.
    Shrestha NK; Burke PC; Nowacki AS; Gordon SM
    PLoS One; 2023; 18(11):e0293449. PubMed ID: 37939032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England.
    Kirsebom FCM; Harman K; Lunt RJ; Andrews N; Groves N; Abdul Aziz N; Hope R; Stowe J; Chand M; Ramsay M; Dabrera G; Kall M; Bernal JL
    Lancet Reg Health Eur; 2023 Dec; 35():100755. PubMed ID: 38115965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronavirus Disease 2019 Vaccine Boosting in Previously Infected or Vaccinated Individuals.
    Shrestha NK; Shrestha P; Burke PC; Nowacki AS; Terpeluk P; Gordon SM
    Clin Infect Dis; 2022 Dec; 75(12):2169-2177. PubMed ID: 35476018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
    Link-Gelles R; Ciesla AA; Fleming-Dutra KE; Smith ZR; Britton A; Wiegand RE; Miller JD; Accorsi EK; Schrag SJ; Verani JR; Shang N; Derado G; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(48):1526-1530. PubMed ID: 36454688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
    Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022.
    Surie D; Bonnell L; Adams K; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Frosch AP; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Khan A; Bender WS; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Rivas C; Kwon JH; Exline MC; Lauring AS; Shapiro NI; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Hart KW; Swan SA; Zhu Y; DeCuir J; Tenforde MW; Patel MM; McMorrow ML; Self WH;
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1327-1334. PubMed ID: 36264830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Necessity of Coronavirus Disease 2019 (COVID-19) Vaccination in Persons Who Have Already Had COVID-19.
    Shrestha NK; Burke PC; Nowacki AS; Terpeluk P; Gordon SM
    Clin Infect Dis; 2022 Aug; 75(1):e662-e671. PubMed ID: 35028662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
    Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
    Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021.
    Starrfelt J; Danielsen AS; Buanes EA; Juvet LK; Lyngstad TM; Rø GØI; Veneti L; Watle SV; Meijerink H
    BMC Med; 2022 Sep; 20(1):278. PubMed ID: 36050718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of the severe acute respiratory syndrome coronavirus 2 Omicron BA.5 bivalent vaccine on symptoms in healthcare workers with BA.5 infection.
    Hirotsu Y; Takatori M; Mochizuki H; Omata M
    Vaccine X; 2024 Mar; 17():100433. PubMed ID: 38299200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer.
    Ehmsen S; Pedersen RM; Bang LL; Asmussen A; Kragh A; Holm DK; Sydenham TV; Jensen TG; Jeppesen SS; Frederiksen H; Andersen TE; Ditzel HJ
    Cancer Cell; 2023 Apr; 41(4):649-650. PubMed ID: 36804967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
    Britton A; Embi PJ; Levy ME; Gaglani M; DeSilva MB; Dixon BE; Dascomb K; Patel P; Schrader KE; Klein NP; Ong TC; Natarajan K; Hartmann E; Kharbanda AB; Irving SA; Dickerson M; Dunne MM; Raiyani C; Grannis SJ; Stenehjem E; Zerbo O; Rao S; Han J; Sloan-Aagard C; Griggs EP; Weber ZA; Murthy K; Fadel WF; Grisel N; McEvoy C; Lewis N; Barron MA; Nanez J; Reese SE; Mamawala M; Valvi NR; Arndorfer J; Goddard K; Yang DH; Fireman B; Ball SW; Link-Gelles R; Naleway AL; Tenforde MW
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1335-1342. PubMed ID: 36264840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy.
    Cheung PK; Lapointe HR; Sang Y; Ennis S; Mwimanzi F; Speckmaier S; Barad E; Dong W; Liang R; Simons J; Lowe CF; Romney MG; Brumme CJ; Niikura M; Brockman MA; Brumme ZL;
    AIDS; 2023 Apr; 37(5):F11-F18. PubMed ID: 36789806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pfizer-BioNTech Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Long-term Care Facility Staff With and Without Prior Infection in New York City, January-June 2021.
    Peebles K; Arciuolo RJ; Romano AS; Sell J; Greene SK; Lim S; Mulready-Ward C; Ternier A; Badenhop B; Blaney K; Real JE; Spencer M; McPherson TD; Ahuja SD; Sullivan Meissner J; Zucker JR; Rosen JB
    J Infect Dis; 2023 Feb; 227(4):533-542. PubMed ID: 36626187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
    Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.